GIPR and breast carcinoma: Though further experimental work is required to validate and clarify potential mechanisms governing this effect, our findings suggesting an adverse association of E354Q with breast cancer risk provide tentative support for a potential protective effect of enhanced GIPR signaling (i.e. GIPR agonism) on breast cancer risk.